Navigation Links
Talecris Biotherapeutics Announces First Quarter 2011 Results
Date:4/27/2011

nhanced by a quantified presentation of the impact of the 2011 Grifols merger-related expenses and interest expense on PCA judgment.  The impacts of these expenses on net income and diluted earnings per share are illustrated in the table below.

The adjusted net income and diluted earnings per share amounts in the table below are non-GAAP financial measures and should not be considered a substitute for any performance measure determined in accordance with U.S. GAAP.  Additional information regarding the use of these non-GAAP financial measures is included in Talecris' Form 10-Q filed with the SEC on April 27, 2011, which is available on SEC's website at www.sec.gov and Talecris' website at http://ir.talecris.com.Diluted EarningsPre-TaxIncome TaxPer(in thousands, except per share amounts)AmountBenefitNet IncomeCommon ShareThree Months Ended March 31, 2011U.S. GAAP$
83,196$
(27,739)$
55,457$
.43Grifols merger-related expenses4,118(1,552)2,5660.02Interest on PCA judgment740(289)451-Excluding specific items$
88,054$
(29,580)$
58,474$
.45Three Months Ended March 31, 2010U.S. GAAP$
8,603$
(23,264)$
45,339$
.35EBITDA, Adjusted EBITDA, and Consolidated Cash FlowTalecris believes that a meaningful analysis of its operating performance is enhanced by the use of EBITDA, adjusted EBITDA as defined in Talecris' revolving credit facility and Consolidated Cash Flow as defined in its 7.75% Notes.

EBITDA, adjusted EBITDA, and Consolidated Cash Flow are financial measures that are not defined by accounting principles generally accepted in the U.S. (U.S. GAAP).  A non-GAAP financial measure is a numerical measure of a company's financial performance that (i) excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in a comparable measure calculated and presented in accordance wi
'/>"/>

SOURCE Talecris Biotherapeutics Holdings Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
7. Talecris Added to NASDAQ Biotechnology Index
8. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
10. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
11. Talecris Biotherapeutics Announces Premerger HSR Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , Jan. 26 The following is a ... PharmAthene, regarding the Commission on the Prevention of Weapons of ... Card by the Commission on the Prevention of Weapons of ... America still remains vulnerable to bioterrorism.  Our Nation,s ability to ...
... , , TUALATIN, Ore. ... Bulletin Board: WYNX), a platform company dedicated to the ... announced that it has reached an agreement with British-based ... second generation Gas Quality Inferential Measurement Device (GasPT2). , ...
... Jan. 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... that it may now enroll patients at US clinical sites ... lead product, nimotuzumab. One of the two trials is in ... treatment and being treated palliatively and the other in patients ...
Cached Biology Technology:Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 2Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 2YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 3YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 5
(Date:7/9/2014)... New Rochelle, NY, July 9, 2014Biofuels derived from the ... alternative to fossil fuels. To achieve this goal, optimization ... as in open pond systems, is needed. Sapphire Energy ... contamination of open pond algae cultivation systems, described in ... Ann Liebert, Inc., publishers. The article is available on ...
(Date:7/9/2014)... a University of Guelph scientist that involved fitting ... exposure to a neonicotinoid pesticide hampers bees, ability ... Nigel Raine, a professor in Guelph,s School of ... London was published July 9 in the British ... The study shows how long-term pesticide exposure affects ...
(Date:7/9/2014)... A new study shows that some shark species may be ... that may come with rising temperatures. , The Arctic today ... but it wasn,t always like that. Roughly 53 to 38 ... epoch, the Arctic was more similar to a huge temperate ... life, including ancestors of tapirs, hippo-like creatures, crocodiles and giant ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Bee foraging chronically impaired by pesticide exposure: Study 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... researchers have identified the job of one of the ... puzzled scientists because it is present in nearly every ... and yet, in laboratory experiments, its function has remained ... enigmatic enzyme known as DinB DNA polymerase is specialized ...
... have identified a handful of microRNAs (miRNAs) that appear ... platelets ?blood cells critical to the body's ability to ... of these same miRNAs, when acting abnormally, may contribute ... that a specific set of miRNA genes are turned ...
... and slow developing gills appear to be keys to ... fish whose adults thrive in icy waters because of ... are important, researchers at the University of Illinois atUrbana-Champaign ... species of notothenioids that inhabit the Ross Sea at ...
Cached Biology News:Common enzyme is a key player in DNA repair 2Common enzyme is a key player in DNA repair 3MiRNA fingerprint identified in platelet formation 2Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: